About this document

Bevacizumab Use for Wet AMD in Europe by Aymen Bekir is a document available to read on EtoBox.

This study analyzes the off-label use of bevacizumab for wet age-related macular degeneration (AMD) across 20 European countries, revealing significant variations in usage rates, from 0% to 97%. The findings indicate a lack of consensus among governmental institutions and ophthalmological societies regarding the treatment, with legal disputes surrounding its use in several countries. Overall, the research highlights the inconsistent application of medical regulations and the ethical implications of off-labe

Author

Aymen Bekir

Language

EN